To 2013, the full-cycle production of wellness devices had been organized: from ideas and research studies to the manufacture of finished products. Already in 2014, production of hardware and software complex ROFES E01C was started on the proprietary manufacturing site. Concurrently, the European certificate of conformity was obtained. Thus, hardware and software complex ROFES E01C became the first device of Inferum Group which was officially certified by the international standards.

Meanwhile, GC “Inferum”, along with mandatory licensing of the manufacturing enterprise and maintenance of medical equipment, was successfully certified for conformity with European quality standards ISO 13485:2016. The receipt of the certificate and annually completed audits indicate that the company is responsible for product quality on all the stages: from the check of components to buyer’s warranty service of finished products.

Since the establishment of Inferum Group, research studies and development of the technology for blood pressure correction have been continuously performed. The experience and knowledge of the team of GC “Inferum”, as well, studies and tests which were carried out in the leading Russian and foreign medical centers have allowed to develop the line of blood pressure correctors. АВР-051 technology has been patented which suggests its uniqueness in the world.

In 2017, GC “Inferum” produced the medical device for hospital use – device APGAR – timer. The device got the marketing authorization for sales in Russia, then won quickly the position on the market, was introduced to the incubation equipment supplied by JSC “Production Association of the Ural Optical and Mechanical Plant”. So Inferum Group also got a strong position on the market of so called “hospital segment” of medical equipment.

After the long-year medical research, in 2019, GC Inferum concluded constant cooperation agreements with the largest medical centers: Federal State Budgetary Institution “Almazov National Medical Research Centre’ of the Ministry of Health of Russia, Izmerov Research Institute of Occupational Health and other largest scientific institutions.

The Inferum Group also does not rest on its laurels in terms of product sales: it is constantly expanding its distribution network internationally. On the Russian market, it has operated to implement medical devices to corporate healthcare programs of large industrial companies.

In 2020, the Inferum Group Board of Directors decided to open a new promising business line: International consulting for the implementation of projects in the field of biomedical technologies. Thus, the first project in this direction was the promotion of the Russian-made single-component vaccine against COVID-19 (SARS-COV-2) “Sputnik Light” to the Islamic Republic of Pakistan.